Cargando…

Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma

This proof-of-concept single-arm open-label phase I clinical trial (NCT02481934) studied the safety and efficacy of multiple infusions of activated and expanded natural killer (NKAE) cells in combination with anti-myeloma drugs in multiple myeloma patients. It included five patients with relapsed or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leivas, Alejandra, Perez-Martinez, Antonio, Blanchard, María Jesús, Martín-Clavero, Estela, Fernández, Lucía, Lahuerta, Juan José, Martinez-Lopez, Joaquín
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5213771/ https://www.ncbi.nlm.nih.gov/pubmed/28123890 http://dx.doi.org/10.1080/2162402X.2016.1250051

Ejemplares similares

Natural killer cells efficiently target multiple myeloma clonogenic tumor cells
por: Leivas, Alejandra, et al.
Publicado: (2021)

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2021)

PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells
por: Guo, Yanan, et al.
Publicado: (2016)

Natural Killer Cells in the Malignant Niche of Multiple Myeloma
por: Venglar, Ondrej, et al.
Publicado: (2022)

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements
por: Cedena, Maria-Teresa, et al.
Publicado: (2020)

Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
por: Thangaraj, Jaya Lakshmi, et al.
Publicado: (2022)

Autologous cellular therapy for myeloma: Giving ex vivo expanded NK cells their due
por: Shapiro, Roman M., et al.
Publicado: (2022)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Myeloma natural killer cells are exhausted and have impaired regulation of activation
por: D’Souza, Criselle, et al.
Publicado: (2021)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2022)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
por: de la Rubia, Javier, et al.
Publicado: (2023)

Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma
por: Rodríguez-García, Alba, et al.
Publicado: (2022)

P1425: ACTIVATED AND EXPANDED NATURAL KILLER CELLS TRANSDUCED WITH AN NKG2D CHIMERIC ANTIGEN RECEPTOR AGAINST ACUTE MYELOID LEUKEMIA
por: Córdoba, L., et al.
Publicado: (2022)

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
por: Ocio, Enrique M., et al.
Publicado: (2023)

The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2021)

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022)

Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model
por: Nur, Haneen, et al.
Publicado: (2013)

Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
por: Pittari, Gianfranco, et al.
Publicado: (2017)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics
por: Alonso, Rafael, et al.
Publicado: (2022)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Autologous transplant for myeloma: when the old meets the new
por: Gay, Francesca, et al.
Publicado: (2017)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY
por: Encinas, Jessica, et al.
Publicado: (2023)

Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease
por: Jiang, Fengjuan, et al.
Publicado: (2018)

Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors
por: Van Elssen, Catharina, et al.
Publicado: (2020)

Tim-3 Blockade Elicits Potent Anti-Multiple Myeloma Immunity of Natural Killer Cells
por: Jiang, Wen, et al.
Publicado: (2022)

NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells
por: Petillo, Sara, et al.
Publicado: (2023)

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations()
por: Lopez, Aurelio, et al.
Publicado: (2015)

Droplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells
por: Carreras, Pilar, et al.
Publicado: (2020)

Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
por: de Queiroz Crusoe, Edvan, et al.
Publicado: (2014)

Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020)

A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
por: Sarkar, Subhashis, et al.
Publicado: (2015)

Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells
por: Bonanni, Valentina, et al.
Publicado: (2019)

Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
por: Nakamura, Ayano, et al.
Publicado: (2021)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Deep Response in Multiple Myeloma: A Critical Review
por: Fulciniti, Mariateresa, et al.
Publicado: (2015)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
por: Puig, Noemi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ctujrluih0l6j853iovgnevgfr